Edition:
United States

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

64.22USD
28 Sep 2016
Change (% chg)

$-0.35 (-0.54%)
Prev Close
$64.57
Open
$64.60
Day's High
$64.85
Day's Low
$63.89
Volume
1,844,903
Avg. Vol
2,512,224
52-wk High
$68.12
52-wk Low
$45.46

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and... (more)

Overall

Beta: 1.50
Market Cap(Mil.): $105,155.00
Shares Outstanding(Mil.): 1,628.54
Dividend: 0.57
Yield (%): 3.53

Financials

  ABBV.N Industry Sector
P/E (TTM): 18.51 36.52 36.51
EPS (TTM): 3.49 -- --
ROI: 11.38 14.40 13.85
ROE: 102.66 15.20 14.77

FDA approves J&J's autoimmune drug Stelara for Crohn's disease

Johnson & Johnson said on Monday that the U.S. Food and Drug Administration approved the company's blockbuster psoriasis drug, Stelara, for use in adults with Crohn's disease.

Sep 26 2016

FDA approves J&J's autoimmune drug Stelara for Crohn's disease

Sept 26 Johnson & Johnson said on Monday that the U.S. Food and Drug Administration approved the company's blockbuster psoriasis drug, Stelara, for use in adults with Crohn's disease.

Sep 26 2016

BRIEF-Karolinska Development: collaboration with AbbVie for Parkinson's Disease Research

* Its portfolio company BioArctic enters into collaboration with AbbVie for Parkinson's Disease Research

Sep 20 2016

BRIEF-Abbvie sets quarterly cash dividend of $0.57per share

* Sets quarterly cash dividend of $0.57per share Source text for Eikon: Further company coverage:

Sep 09 2016

Pfizer boosts cancer drug roster with $14 billion Medivation deal

Pfizer Inc , beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster. | Video

Aug 22 2016

UPDATE 5-Pfizer boosts cancer drug roster with $14 bln Medivation deal

Aug 22 Pfizer Inc, beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster.

Aug 22 2016

Elliott Associates sues AbbVie over failed bid for Shire

Aug 5 AbbVie Inc said hedge fund Elliott Associates LP has sued the pharmaceuticals company alleging that it had made misrepresentations and omissions related to a failed attempt to buy Dublin-based Shire Plc .

Aug 05 2016

Drugmaker AbbVie bumps up profit forecast on strong Humira sales

AbbVie Inc posted higher-than-expected quarterly profit and revenue, driven by demand for its flagship drug Humira, and raised its earnings forecast for the year.

Jul 29 2016

UPDATE 2-Drugmaker AbbVie bumps up profit forecast on strong Humira sales

July 29 AbbVie Inc posted higher-than-expected quarterly profit and revenue, driven by demand for its flagship drug Humira, and raised its earnings forecast for the year.

Jul 29 2016

AbbVie revenue jumps 17.8 pct on higher demand for drug Humira

July 29 AbbVie Inc's quarterly net revenue jumped 17.8 percent, driven by demand for its top-selling treatment, Humira.

Jul 29 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : S&P Capital IQ – STARS Reports
$127.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.